Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 3 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 3 | 4 |
| 2004 | 2 | 7 | 9 |
| 2005 | 4 | 2 | 6 |
| 2006 | 1 | 4 | 5 |
| 2007 | 3 | 7 | 10 |
| 2008 | 3 | 3 | 6 |
| 2009 | 3 | 5 | 8 |
| 2010 | 5 | 6 | 11 |
| 2011 | 2 | 1 | 3 |
| 2012 | 4 | 6 | 10 |
| 2013 | 5 | 5 | 10 |
| 2014 | 5 | 7 | 12 |
| 2015 | 6 | 6 | 12 |
| 2016 | 4 | 9 | 13 |
| 2017 | 3 | 13 | 16 |
| 2018 | 4 | 10 | 14 |
| 2019 | 4 | 4 | 8 |
| 2020 | 3 | 8 | 11 |
| 2021 | 1 | 5 | 6 |
| 2022 | 4 | 9 | 13 |
| 2023 | 3 | 8 | 11 |
| 2024 | 2 | 9 | 11 |
| 2025 | 6 | 4 | 10 |
| 2026 | 1 | 7 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Pathologic failure and salvage approaches following focal therapy for localized prostate cancer. Can J Urol. 2026 Aug 21; 33(4):799-810.
-
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 29; 408(10557):793-807.
-
Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous. JAMA Oncol. 2026 07 01; 12(7):767-771.
-
Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up. Ann Intern Med. 2026 Jul; 179(7):988-995.
-
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. Nat Commun. 2026 May 08; 17(1).
-
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2026 Aug; 24(5):102570.
-
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026 03 14; 407(10533):1059-1071.
-
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. Clin Cancer Res. 2026 Feb 04; 32(3):479-488.
-
Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging. J Natl Cancer Inst. 2025 Nov 01; 117(11):2308-2316.
-
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. Eur Urol. 2026 Jan; 89(1):82-90.